)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Double Bond Pharmaceutical
Double Bond Pharmaceutical (DBP) investor relations material
Double Bond Pharmaceutical Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary27 Aug, 2026
Executive summary
Ongoing negotiations with four potential partners, including two pharmaceutical companies and two financial investors, focused on Temodex and SI053 products.
Preparing a supplementary cohort analysis based on MGMT status to strengthen RWE study evidence for Temodex.
Active preparations for major medical congress presentations and commercialization of Temodex in Turkey, China, and Mexico.
Financial highlights
Total revenue for Q2 2026 and H1 2026 was 0.0 MSEK, unchanged year-over-year.
Operating loss for Q2 2026 was -0.6 MSEK (vs. -0.4 MSEK Q2 2025); H1 2026 operating loss was -0.9 MSEK (vs. -0.8 MSEK H1 2025).
Net loss for Q2 2026 was -0.6 MSEK (vs. -0.4 MSEK Q2 2025); H1 2026 net loss was -0.9 MSEK (improved from -1.5 MSEK H1 2025).
Earnings per share for H1 2026 was -0.00 SEK (vs. -0.02 SEK H1 2025).
Cash and cash equivalents at June 30, 2026, were 239,519 SEK (vs. 255,067 SEK June 30, 2025).
Outlook and guidance
Focus remains on advancing negotiations, completing the MGMT cohort analysis, maximizing congress presence, and commercializing Temodex in key markets.
Next financial report scheduled for November 25, 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Double Bond Pharmaceutical
- Q1 2026 delivered narrowed losses and major clinical validation for Temodex.DBP
Q1 2026 - Breakthroughs in SI053/Temodex and improved financials position for future growth.DBPQ4 2025
- Improved results and restored equity as S1053 advances toward potential partnerships.DBPQ3 2025
- Revenue and net loss improved, with strong project progress and a major rights issue launched.DBPQ2 2025
- SI-053 clinical trial preparations advanced, with improved results and new financing secured.DBPQ3 2024
- SI-053 clinical progress and new partnerships drive Double Bond Pharmaceutical's strategic focus.DBPQ2 2024
- Losses narrowed as SI-053 advanced; funding secured, liquidity sufficient into Q3 2025.DBPQ4 2024
- Revenues rose and losses narrowed as SI053 clinical trial preparations were completed.DBPQ1 2025
Next Double Bond Pharmaceutical earnings date
Q3 202625 Nov, 2026
Double Bond Pharmaceutical
Next Double Bond Pharmaceutical earnings date
Q3 202625 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Double Bond Pharmaceutical International AB is a Sweden-based pharmaceutical company specializing in the development of innovative therapies for cancer and infectious diseases. The company focuses on utilizing advanced drug delivery technologies to improve the efficacy and safety of treatments. Double Bond Pharmaceutical’s research and development efforts aim to address unmet medical needs and provide targeted solutions for patients. The company is headquartered in Uppsala, Sweden, and its shares are listed on the Spotlight Stock Market.